- PROFESSOR Medicine, Infectious Diseases
American Board of Internal Medicine
Residency, Internal Medicine
Lincoln Medical & Mental Health Ct.
Fellowship, Infectious Diseases
Beth Israel Medical Center
I have served as the Medical Director of the Peter Krueger (PKC) since 2000. PKC provides longitudinal HIV and primary care to ~1200 HIV infected persons together with onsite mental health, nutrition, case management, adherence/care coordination and specialty services (dermatology and pain management). PKC has an operating budget of $2.1 millions plus $1.5 millions in grant funding and a staff of 62 of whom are grant funded including 4 Infectious Diseases Fellows who have each one weekly clinic session. I have made several important contributions including the customization of the EMR that has resulted to into better quality outcomes and to the development of a research capacity, more structured fellow education using dedicated attending physicians, development of a capacity to treat Hepatitis via a prior NY state funded Hepatitis C grant, improved monitoring of chronic opioid therapy, the implementation of NY State funded care coordination and treatment adherence for HIV treatment failures, the smooth transition to managed care, and recent contributions to the Mount Sinai System including workflow modifications, Hepatitis C education grant application and HIV Quality Program design.
I have been a full staff member of the Department of Medicine, Division of Infectious Diseases since July 1989 and have contributed each at least 3-4 months/year to the teaching and supervision of Internal Medicine residents and Infectious Diseases Fellow together with several didactic lectures. I oversee the outpatient training of 4 Infectious Diseases Fellow at the Peter Krueger Clinic and am directly responsible for the teaching of one ID fellows (4 hours/week). I have served in several leadership teaching positions including coordinator of TB/Pulmonary ID rounds and Clerkship Director for sub interns rotating at Beth Israel. I have an excellent tract record in mentoring ID fellows and residents in clinical research. I am a recipient of the Beth Israel Teaching Award and my teaching evaluations have been consistently above my peer group.
I followed a cohort of about ~120 HIV infected patients at the Peter Krueger clinic and I am responsible for the supervision of one nurse practitioner. I have a growing faculty practice and I provide direct care to ~500 HIV infected patients at the Phillips Ambulatory care clinic together with consultative services about general ID cases and travel medicine. All of my referrals have come from my patients and from my peers. I am local, national, and international resource for difficult for complex to manage HIV and TB cases. I have been nominated NY Super Doctor 5 times in the past 6 years.
New York Super Doctor
New York City Super Doctor
New York City Super Doctor
New York City Super Doctor
1993 Teacher of the year - can be nominated only once
Beth Israel Society for the Teaching of Medicine
New York Super Doctor
Top Doctor in NY, International Association of Internists, The Leading Physicians of the World
My main scientific interest interests have been in the fields of HIV and HIV-related opportunistic infections. I have made important contributions towards improved therapies for acyclovir-resistant mucocutaneous herpes simplex infection and cryptococcal meningitis and towards the description of clinical features and risk factors of invasive aspergillosis and CMV pneumonia. I have made major contributions to the field of tuberculosis including the design and implementation of TB screening in needle exchange attendees and of directly observed outpatient TB and HIV treatment, the association of early identification of MDR-TB and DOT with improved MDRT-TB outcomes in both HIV negative and HIV positive patients, and the critical role of HIV-related immune suppression rather than resistance per se in HIV-TB mortality. My research have not only informed the conduct of TB DOT in New York City but also the design of several national multicenter studies including ACTG 222 (Treatment of Pulmonary TB in HIV-infected persons), ACTG 309 (PK of antituberculosis agents in HIV infected patients), ACTG 5073 (Utility of outpatient DOT) in HIV. I have collaborated with several agencies/institutions (CDC, NYC Health Department, Columbia University, New York University, TB Trials Consortium, NYC Tuberculosis Group) on study projects towards improving therapies for HIV-TB and adherence to HIV antiretroviral therapies, epidemiology of TB resitance, and interventions to reduce substance abuse in HIV infected persons (see CV). I have served as a research mentor for 25 residents and fellows; their research findings have been published at national and nternational conferences (see CV). My research will continue to focus on improved treatment outcomes in HIV and Hepatitis C and I will continue to serve as a mentor for students, residents and fellows.
Soni A, Argawal A, Chander P, Yoo J, Singal D, Salomon N, Robinson B, Treser G. Evidence for an HIV-related nephropathy: a clinico-pathological study. Clinical Nephrology 1989;31:12-17. . Conception and design . Data collection.;.
Klapholz A, Salomon N, Perlman DC, Talavera W. Invasive aspergillosis in the acquired immunodeficiency syndrome: Clinical manifestations and predisposing factors. Chest 1991; 100:1614-18..;.
Salomon N, Perlman DC, DePalo V, Kolokathis A, Wilets I. Rise in initial and acquired drug-resistant tuberculosis in a largely HIV-infected urban population: Factors associated with resistance. Mt Sinai J Med. 1994; 61: 341-347..;.
Goldstein S, Perlman DC, Salomon N. Two-stage tuberculin skin testing in an HIV-infected population. Mt Sinai J of Med. 1994; 61 337-340..;.
Telzak E, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, Blum S, Gagliardi A, Salomon N, Turett G. Multidrug-resistant tuberculosis among patients without HIV infection. N Engl J Med 1995; 333:907-11..;.
Salomon N, Perlman DC, Friedmann, Buchstein S, Kreisworth BN, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21:1245-52.;.
Perlman DC, Perkins MP, Salomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. Am J Public Health 1997; 87: 862-3..;.
Perlman DC, Perkins MP, Paone D, Kochems L, Salomon N, Des Jarlais DC. .;.
Salomon N, Gomez T, Perlman DC, Laya L, Eber C, Mildvan D. Clinical features of and outcome of HIV-related Cytomegalovirus pneumonia. AIDS 1997; 11:319-324.;.
Salomon N, Perlman DC, Rubenstein A, Mandelman D, McKinley FM, Yancovitz SR. Implementation of universal directly observed therapy at a New York City Hospital and evaluation of an outpatient directly observed therapy program. Int J Tuberc Lung Dis 1997; 1(5):397-404.;.
Friedman CR, Quinn GC, Kreiswirth BN, Perlman DC, Salomon N, Schulger N, Lutfey M, Berger J, Poltoratskia N, Riley L. Widespread dissemination of a single drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis 1997; 176: 478-84..;.
Perlman DC, Wafaa M. El-Sadr, Eileen T. Nelson, John P. Matts, Telzak EE, Salomon N,Chirgwin K, Hafner R, and the Terry Beirn Community Programs for Clinical Research on AIDS and the AIDS Clinical Trials Group. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression Clin Infect Dis 1997; 25:242-246.;.
Perlman DC, Wafaa M. El-Sadr, Leonid B. Heifets, Eileen T. Nelson, John P. Matts, Chirgwin K, Salomon N, Telzak EE, Oscar Klein, Barry N. Kreiswirth, James M. Musser, and Hafner R for the Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 protocol team. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11:473-478..;.
El-Sadr W, Perlman DC, Matts J, Eileen TN, Cohn D, Salomon N, Olibrice M, Medard F, Mildvan D, Jones BE, Telzak EE, Klein O, Hafner R, and the Terry Beirn Community Programs for Clinical Research on AIDS and the AIDS Clinical Trials Group. Evaluation of an intensive Intermittent-Induction Regimen and Duration of Short-Course Treatment for Human Immnunodeficiency Virus-Related Pulmonary Tuberculosis. Clin Infect Dis 1998; 26:1148-1158..;.
Denise Paone, David C. Perlman, Mary Patricia Perkins, Lee M. Kochems, Salomon N, Don C. Des Jarlais. Organizational Issues in conducting tuberculosis screening at a syringe exchange. Journal of substance Abuse Treatment 1997; 14 (5):1-5..;.
Salomon N, DC Perlman, Mary M Perkins, Patricia Friedmann, Denise Paone, Victoria Gracia De Soria, Don C Des Jarlais Knowledge of tuberculosis among drug users: Relationship to tuberculosis status and screening return rates. Journal of Substance Abuse Treatment 1998; 16 : 229-235..;.
Balamurali K. Ambati, David C. Perlman, Salomon N. Outcomes of G-CSF/GM-CSF use in neutropenic HIV-infected patients patients. Int J Infect Dis 1998-99; 3:70-5..;.
Stancliff S, Salomon N, Perlman DC, Russell PC. Feasibility of providing influenza and pneumococcal vaccines to active drug injectors at a syringe exchange program Journal of substance Abuse Treatment 2000; 18: 263-5..;.
Perlman DC, Henman A, Kochems L, Paone D, Salomon N, Des Jarlais D. Doing a shotgun: a drug use practice and its relationship to sexual behavior and infection risk. Soc Sci Med 1999; 48:1441-8..;.
Salomon N, Perlman DC, Friedmann, P, Ziluck V, and, Des Jarlais D. Prevalence and risk factors for positive tuberculin test among active drug users at a syringe exchange. Int J Tuberc Lung Dis 2000; 4(1):47-54..;.
Salsitz EA. Joseph H, Frank B, Perez J. Richman BL, Salomon N, Kalin MF, Novick DM. Methadone medical maintenance (MMM): treating chronic opioid dependence in a private medical practice – a summary report (1983-1998). Mt Sinai J of Medicine 2000; 67:388-397..;.
Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC. Cost effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a synringe exchange program. J of Urban Health 2001: 78:552-569..;.
Perlman DC, Friedmann P, Horn L, Nugent A, Schoeb V, Carey J, Salomon N, Des Jarlais DC. Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange based tuberculin skin testing. Journal of Urban Health 2003: 80:28-37..;.
Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Rmmel RP. Chirgwin, Salomon N, Hafner R for the ACTG 309 Team. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clinical Infectious Diseases 2004:38; 556-64..;.
Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA for the ACTG 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clinical Infectious Disease, 2005; 41 (11): 1638-1647..;.
Gross Robert; Tierney Camlin; Andrade Adriana; Lalama Christina; Rosenkranz Susan; Eshleman Susan H; Flanigan Timothy; Santana Jorge; Salomon Nadim; Reisler Ronald; Wiggins Ilene; Hogg Evelyn; Flexner Charles; Mildvan Donna. Modified directly observed antiretroviral therapy compared with self-administered therapy on treatment-naïve HIV-1 infected patients: a randomized trial. Archives of internal medicine 2009;169(13):1224-32..;.
Masako Mizusawa, David C. Perlman, David Lucido, Nadim Salomon. Loss of vaccine acquired HBsAb after 3 doses of hepatitis B vaccination in HIV-infected persons Short title: Loss of vaccine-acquired HBsAb in HIV. International Journal of AIDS and STDs, August 2013.;.
HIV-infected individuals who delay, decline, or discontinue antiretroviral therapy: comparing clinic- and peer-recruited cohorts. Marya Gwadz, Elizabeth Applegate, Charles Cleland, Noelle Regina Leonard, Hannah Wolfe, Nadim Salomon, Mindy Belkin, Marion Riedel, Angela Banfield, Lisa Sanfillipo, AndreaWagner , Donna Mildvan and The Heart to Heart Collaborative Research Team. Frontiers in Public Health, July 2014; 10:3389..;.
Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention. Gwadz M, Cleland CM, Applegate E, Belkin M, Gandhi M, Salomon N, Banfield A, Leonard N, Riedel M, Wolfe H, Pickens I, Bolger K, Bowens D, Perlman D, Mildvan D; Heart to Heart Collaborative Research Team. AIDS Behav. 2015 Apr 3..;.
Perlman DC, Salomon N, Perkins MP, Yancovits S, Des Jarlais D. Tuberculosis in drug users. Clin infect Dis 1995; 21:1253-64.;.
Salomon N, David C. Perlman. Cytomegalovirus pneumonia in HIV-infected patients. Seminar in Respiratory Infection. Semin Respir Infect. 1999 Dec;14(4):353-8.;.
Salomon N and Perlman DC. Multidrug-resistant Tuberculosis: Globally with us for the long haul. Clin Infect Dis 1999; 29:93-95.;.
David C. Perlman, Phillip El Helou, Salomon N. Tuberculosis in patients with human immunodeficiency virus infection. Seminar in Respiratory Infections 1999; 14:344-352..;.
Perlman DC, D’ Amico R, Salomon N. Mycobacterial Infections of the head and neck. Current Infectious Diseases Reports 2001. 3: 233-241..;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Salomon did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.